References
- Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-pd-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2411.
- Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016 Apr 19;315(15):1600–1609.
- Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22;372(4):320–330.
- Kaunitz GJ, Cottrell TR, Lilo M, et al. Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Lab Investig J Tech Methods Pathol. 2017 Sep;97(9):1063–1071.
- Madore J, Vilain RE, Menzies AM, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2015 May;28(3):245–253.
- Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–289.
- Hessvik NP, Llorente A. Current knowledge on exosome biogenesis and release. Cell Mol Life Sci CMLS. 2018;75(2):193–208.
- Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569–579.
- Kowal J, Arras G, Colombo M, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968–977.
- Cordonnier M, Chanteloup G, Isambert N, et al. Exosomes in cancer theranostic: diamonds in the rough. Cell Adhes Migr. 2017 Mar 4;11(2):151–163.
- Kalluri R. The biology and function of exosomes in cancer. J Clin Invest. 2016 Apr 1;126(4):1208–1215.
- Théry C, Amigorena S, Raposo G, et al. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22.
- Sheridan C. Exosome cancer diagnostic reaches market. Nat Biotechnol. 2016 Apr;34(4):359–360.
- Theodoraki M-N, Yerneni SS, Hoffmann TK, et al. Clinical significance of PD-L1+ exosomes in plasma of head and neck cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2018 Feb 15;24(4):896–905.
- Ludwig S, Floros T, Theodoraki M-N, et al. Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer. Clin Cancer Res. 2017 Aug 15;23(16):4843–4854.
- Ricklefs FL, Alayo Q, Krenzlin H, et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv. 2018 Mar;4(3):eaar2766.
- Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382–386.
- Poggio M, Hu T, Pai -C-C, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019 Apr 4;177(2):414–427.e13.
- Nishino M, Giobbie-Hurder A, Gargano M, et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res Off J Am Assoc Cancer Res. 2013 Jul 15;19(14):3936–3943.
- Soluble PD-L1 as a biomarker in malignant melanoma and checkpoint blockade | Cancer immunology research [Internet]. [cited 2019 Feb 12]. Available from: http://cancerimmunolres.aacrjournals.org/content/early/2017/05/18/2326-6066.CIR-16-0329
- Gobbo J, Marcion G, Cordonnier M, et al. Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer. J Natl Cancer Inst. 2016 Mar;108(3), djv330.
- Sage PT, Schildberg FA, Sobel RA, et al. Dendritic cell PD-L1 limits autoimmunity and follicular T cell differentiation and function. J Immunol. 2018 Apr 15;200(8):2592–2602.
- Gibbons Johnson RM, Dong H. Functional expression of programmed death-ligand 1 (B7-H1) by immune cells and tumor cells. Front Immunol [Internet]. 2017 Aug 10;8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554355/
- Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol [Internet]. 2017 Aug 23;8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572324/
- Lu C, Redd PS, Lee JR, et al. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. Oncoimmunology. 2016;5(12):e1247135.
- Hartley GP, Chow L, Ammons DT, et al. Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation. Cancer Immunol Res. 2018 Oct;6(10):1260–1273.
- Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1) | PNAS [Internet]. [cited 2019 Feb 12]. Available from: https://www.pnas.org/content/115/43/E10119
- PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers | Annals of oncology | Oxford academic [Internet]. [cited 2019 Feb 12]. Available from: https://academic.oup.com/annonc/article-abstract/29/10/2085/5079837
- Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–2608.
- Kowanetz M et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proc Natl Acad Sci U S A. 2018;23;115(43):E10119–E10126.
- Sabari JK, Leonardi GCShu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018;1;29(10):2085–2091.
- Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017;16(11):25-98-2608.